Seat­tle Ge­net­ic­s' armed an­ti­body scores high in front­line blad­der can­cer, tak­ing cen­ter stage at ES­MO

BARCELONA — Seat­tle Ge­net­ics and Astel­las are off to a strong start in ex­pand­ing their fran­chise for the armed an­ti­body en­for­tum­ab ve­dotin — be­fore it’s ac­tu­al­ly on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER